Spark Therapeutics Inc. (NASDAQ:ONCE)’s share price traded up 4.6% during trading on Friday . The stock traded as high as $58.19 and last traded at $57.94, with a volume of 844,432 shares trading hands. The stock had previously closed at $55.39.

ONCE has been the subject of several analyst reports. Chardan Capital set a $35.00 price target on shares of Spark Therapeutics and gave the company a “hold” rating in a research note on Thursday, July 21st. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Spark Therapeutics in a research note on Thursday, July 14th. Royal Bank Of Canada initiated coverage on shares of Spark Therapeutics in a research note on Tuesday, July 12th. They set an “outperform” rating and a $70.00 price target for the company. SunTrust Banks Inc. raised their price target on shares of Spark Therapeutics from $64.00 to $72.00 and gave the company a “buy” rating in a research note on Tuesday, June 21st. Finally, Jefferies Group reaffirmed a “hold” rating on shares of Spark Therapeutics in a research note on Sunday, June 12th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $58.70.

The company has a 50 day moving average price of $51.46 and a 200-day moving average price of $39.72. The company’s market capitalization is $1.59 billion.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Wednesday, May 4th. The company reported ($0.95) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.84) by $0.11. The business had revenue of $1.29 million for the quarter, compared to analyst estimates of $1.48 million. Spark Therapeutics’s revenue was down 43.2% on a year-over-year basis. On average, equities analysts predict that Spark Therapeutics Inc. will post ($3.81) EPS for the current fiscal year.

In other Spark Therapeutics news, CEO Jeffrey D. Marrazzo sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 18th. The shares were sold at an average price of $52.53, for a total value of $262,650.00. Following the completion of the transaction, the chief executive officer now owns 235,000 shares of the company’s stock, valued at approximately $12,344,550. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Anand Mehra sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, May 31st. The stock was sold at an average price of $60.00, for a total transaction of $30,000.00. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Spark Therapeutics stock. UBS Oconnor LLC purchased a new position in Spark Therapeutics Inc. (NASDAQ:ONCE) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 97,000 shares of the company’s stock, valued at approximately $4,395,000. UBS Oconnor LLC owned about 0.39% of Spark Therapeutics at the end of the most recent reporting period.

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.